Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

Abstract Increasing number of Janus kinase (JAK) inhibitors have been approved for chronic haematopoietic neoplasms and inflammatory/autoimmune diseases. We aimed to assess safety of the first three approved JAK inhibitors: ruxolitinib, tofacitinib and baricitinib. In this retrospective observationa...

Full description

Bibliographic Details
Main Authors: Léa Hoisnard, Bénédicte Lebrun-Vignes, Sébastien Maury, Matthieu Mahevas, Khalil El Karoui, Lydia Roy, Anissa Zarour, Marc Michel, José L. Cohen, Aurélien Amiot, Pascal Claudepierre, Pierre Wolkenstein, Philippe Grimbert, Emilie Sbidian
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-10777-w

Internet

https://doi.org/10.1038/s41598-022-10777-w

Similar Items